Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 May 18;82(12):1952–1957. doi: 10.1054/bjoc.2000.1147

The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer

A M Cook 1, R A Huddart 1, G Jay 1, A Norman 1, D P Dearnaley 1, A Horwich 1
PMCID: PMC2363245  PMID: 10864203

Abstract

In patients with advanced bladder cancer receiving chemotherapy, early assessment of response can avoid unnecessary toxicity. The aim of this study was to assess the role of tumour markers in monitoring response. Serum levels of one or more of markers β human chorionic gonadotrophin (βhCG), carcinoembryomic antigen (CEA), CA125 and CA19.9 were measured in 74 patients with advanced bladder cancer receiving chemotherapy from 1992 to 1997. Forty-three of 74 (58%) of patients had at least one raised marker (1.5 times upper limit of normal range). This was more common in patients with extra-pelvic disease than in those with disease confined to the pelvis (P= 0.002). Thirty-eight of 78 (49%) assessable patients had a radiological response. Neither clinical response (P= 0.81) nor survival (P= 0.16) differed between marker-negative and marker-positive patients. Clinical response was strongly related to marker response in the 35 comparable patients (P= 0.0001). No patient had a clinical response without response of at least one marker. Ninety per cent of patients who achieved a marker response had done so by 8 weeks. Monitoring of tumour markers in patients with advanced bladder cancer can help predict the response to chemotherapy. © 2000 Cancer Research Campaign

Keywords: bladder cancer, chemotherapy, tumour markers

Full Text

The Full Text of this article is available as a PDF (69.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abel P. D., Cornell C., Buamah P. K., Williams G. Assessment of serum CA 19.9 as a tumour marker in patients with carcinoma of the bladder and prostate. Br J Urol. 1987 May;59(5):427–429. doi: 10.1111/j.1464-410x.1987.tb04840.x. [DOI] [PubMed] [Google Scholar]
  2. Dexeus F., Logothetis C., Hossan E., Samuels M. L. Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies. J Urol. 1986 Aug;136(2):403–407. doi: 10.1016/s0022-5347(17)44882-8. [DOI] [PubMed] [Google Scholar]
  3. Fosså S. D., Sternberg C., Scher H. I., Theodore C. H., Mead B., Dearnaley D., Roberts J. T., Skovlund E. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer. 1996 Nov;74(10):1655–1659. doi: 10.1038/bjc.1996.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Guarnaccia S., Pais V., Grous J., Spirito N. Adenocarcinoma of the urachus associated with elevated levels of CA 125. J Urol. 1991 Jan;145(1):140–141. doi: 10.1016/s0022-5347(17)38271-x. [DOI] [PubMed] [Google Scholar]
  5. Iles R. K., Jenkins B. J., Oliver R. T., Blandy J. P., Chard T. Beta human chorionic gonadotrophin in serum and urine. A marker for metastatic urothelial cancer. Br J Urol. 1989 Sep;64(3):241–244. doi: 10.1111/j.1464-410x.1989.tb06006.x. [DOI] [PubMed] [Google Scholar]
  6. Iles R. K., Persad R., Trivedi M., Sharma K. B., Dickinson A., Smith P., Chard T. Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol. 1996 Jan;77(1):61–69. doi: 10.1046/j.1464-410x.1996.82910.x. [DOI] [PubMed] [Google Scholar]
  7. Loehrer P. J., Sr, Einhorn L. H., Elson P. J., Crawford E. D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M. F., Lowe B. A. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992 Jul;10(7):1066–1073. doi: 10.1200/JCO.1992.10.7.1066. [DOI] [PubMed] [Google Scholar]
  8. Logothetis C. J., Dexeus F. H., Finn L., Sella A., Amato R. J., Ayala A. G., Kilbourn R. G. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990 Jun;8(6):1050–1055. doi: 10.1200/JCO.1990.8.6.1050. [DOI] [PubMed] [Google Scholar]
  9. Marcillac I., Cottu P., Théodore C., Terrier-Lacombe M. J., Bellet D., Droz J. P. Free hCG-beta subunit as tumour marker in urothelial cancer. Lancet. 1993 May 22;341(8856):1354–1355. doi: 10.1016/0140-6736(93)90872-e. [DOI] [PubMed] [Google Scholar]
  10. Marcillac I., Troalen F., Bidart J. M., Ghillani P., Ribrag V., Escudier B., Malassagne B., Droz J. P., Lhommé C., Rougier P. Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res. 1992 Jul 15;52(14):3901–3907. [PubMed] [Google Scholar]
  11. Maulard-Durdux C., Toubert M. E., Hennequin C., Housset M. Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study. J Clin Oncol. 1997 Dec;15(12):3446–3450. doi: 10.1200/JCO.1997.15.12.3446. [DOI] [PubMed] [Google Scholar]
  12. McLoughlin J., Pepera T., Bridger J., Williams G. Serum and urinary levels of beta human chorionic gonadotrophin in patients with transitional cell carcinoma. Br J Cancer. 1991 May;63(5):822–824. doi: 10.1038/bjc.1991.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Moutzouris G., Yannopoulos D., Barbatis C., Zaharof A., Theodorou C. Is beta-human chorionic gonadotrophin production by transitional cell carcinoma of the bladder a marker of aggressive disease and resistance to radiotherapy? Br J Urol. 1993 Dec;72(6):907–909. doi: 10.1111/j.1464-410x.1993.tb16294.x. [DOI] [PubMed] [Google Scholar]
  14. Pectasides D., Bafaloucos D., Antoniou F., Gogou L., Economides N., Varthalitis J., Dimitriades M., Kosmidis P., Athanassiou A. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol. 1996 Jun;19(3):271–277. doi: 10.1097/00000421-199606000-00013. [DOI] [PubMed] [Google Scholar]
  15. Schmidt A., Bub P., Rüther U., Eisenberger F. Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy. Eur Urol. 1992;21 (Suppl 1):10–12. doi: 10.1159/000474879. [DOI] [PubMed] [Google Scholar]
  16. Sternberg C. N., Yagoda A., Scher H. I., Watson R. C., Herr H. W., Morse M. J., Sogani P. C., Vaughan E. D., Jr, Bander N., Weiselberg L. R. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988 Mar;139(3):461–469. doi: 10.1016/s0022-5347(17)42494-3. [DOI] [PubMed] [Google Scholar]
  17. Williams G., Colbeck R. A., Crawford S. M. Treatment of bladder carcinoma using a germ cell chemotherapy protocol. Br J Urol. 1990 May;65(5):473–477. doi: 10.1111/j.1464-410x.1990.tb14789.x. [DOI] [PubMed] [Google Scholar]
  18. Wurzel R. S., Yamase H. T., Nieh P. T. Ectopic production of human chorionic gonadotropin by poorly differentiated transitional cell tumors of the urinary tract. J Urol. 1987 Mar;137(3):502–504. doi: 10.1016/s0022-5347(17)44088-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES